COLLABORATION AGREEMENT BY AND BETWEEN OREXIGEN THERAPEUTICS, INC. AND TAKEDA PHARMACEUTICAL COMPANY LIMITED DATED SEPTEMBER 1, 2010Collaboration Agreement • November 4th, 2010 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations • New York
*** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
AMENDMENT NO. 1 TO LICENSE AGREEMENTLicense Agreement • November 4th, 2010 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations
This Amendment No. 1 to License Agreement (the “Amendment No. 1”), effective as of August 28, 2010 (the “Amendment No. 1 Effective Date”) by and between Lee G. Dante, an individual having his principal office at [***] (“Dante”), and Orexigen Therapeutics, Inc., a corporation organized under the laws of Delaware, with its corporate headquarters and principal office at 3344 N. Torrey Pines Court, Suite 200, La Jolla, California 92037 (“Orexigen”).
